feedsFeeds PubMed

Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies


Review


doi: 10.1007/s12032-024-02559-3.

Affiliations

Item in Clipboard

Review

Shaza Hammad et al.


Med Oncol.


.

Abstract

Recent advancements in cancer immunotherapy have spotlighted the PD-1/PD-L1 pathway, crucial for its role in immune checkpoint regulation. Traditional inhibitors, though successful, face challenges like resistance and adverse effects. Bispecific antibodies targeting PD-1 and PD-L1 present a ground-breaking solution by simultaneously engaging multiple immune regulatory molecules. Developments in PD-1/PD-L1 bispecific antibodies up to now have been summarized, and the latest findings from the 2024 ASCO conference are presented, revealing that bispecific antibodies exhibit robust efficacy in treating various types of cancers, marking a significant step forward in cancer treatment.


Keywords:

Bispecific antibodies; Cancer immunotherapy; Immune checkpoint regulation; PD-1 inhibitors; PD-1/PD-L1 pathway; PD-L1 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations Conflicts of interest The authors declare no competing interests.

References

    1. Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. https://doi.org/10.1186/s12943-019-0974-6 .



      DOI



      PubMed



      PMC

    1. Liu R, et al. IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: a phase I dose-escalation study. J Clin Oncol. 2024;42(16_suppl):e14506–e14506. https://doi.org/10.1200/JCO.2024.42.16_suppl.e14506 .



      DOI

    1. Wu L, et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. J Clin Oncol. 2024;42(16_suppl):5524–5524. https://doi.org/10.1200/JCO.2024.42.16_suppl.5524 .



      DOI

    1. Wu C, et al. A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC. J Clin Oncol. 2024;42(16_suppl):8533–8533. https://doi.org/10.1200/JCO.2024.42.16_suppl.8533 .



      DOI

    1. Falchook GS, et al. Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4–1BB, in advanced solid tumors. J Clin Oncol. 2024;42(16_suppl):2529–2529. https://doi.org/10.1200/JCO.2024.42.16_suppl.2529 .



      DOI

MeSH terms

Substances


Fonte original PubMed

Artigos relacionados

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *

Botão Voltar ao topo

Adblock detectado

Por favor, considere apoiar-nos, desativando o seu bloqueador de anúncios